MicroRNA‑148b inhibits proliferation and the epithelial‑mesenchymal transition and increases radiosensitivity in non‑small cell lung carcinomas by regulating ROCK1

Luo,Haitao; Liang,Caixia

doi:10.3892/etm.2018.5845

MicroRNA‑148b inhibits proliferation and the epithelial‑mesenchymal transition and increases radiosensitivity in non‑small cell lung carcinomas by regulating ROCK1

Authors:
- Haitao Luo
- Caixia Liang
View Affiliations

Affiliations: Department of Oncology 2 Division, Foshan Nanhai District People's Hospital, Foshan, Guangdong 528200, P.R. China, Department of Respiratory Medicine, Foshan Nanhai District People's Hospital, Foshan, Guangdong 528200, P.R. China
Published online on: February 7, 2018 https://doi.org/10.3892/etm.2018.5845
Pages: 3609-3616

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) accounts for ~80% of all types of lung cancer, which has the highest morbidity and mortality of all types of cancer worldwide. It is important to identify novel biomarkers and the molecular mechanism of NSCLC to improve current treatments of NSCLC. The present study aimed to investigate the effect of miR‑148b expression on the proliferation, epithelial‑mesenchymal transition (EMT) and radiosensitivity of NSCLC cells. It was demonstrated that miR‑148b expression was significantly decreased in NSCLC tissues and cell lines. A549 cells were then transfected with a miR‑148b mimic and a miR‑148b inhibitor. Transfection with the miR‑148b mimic decreased proliferation whereas transfection with the miR‑148b inhibitor increased the proliferation of A549 cells. Additionally, the miR‑148b mimic increased E‑cadherin expression and decreased N‑cadherin and vimentin expression. By contrast, transfection with the miR‑148b inhibitor decreased E‑cadherin expression and increased N‑cadherin and vimentin expression. Irradiation‑induced cell death was significantly promoted by the miR‑148b mimic but inhibited by the miR‑148b inhibitor. The miR‑148b mimic significantly decreased the expression of Rho‑associated protein kinase 1 (ROCK1) and it was demonstrated that overexpression of ROCK1 significantly inhibited the effects of miR‑148b on cell proliferation, the EMT and irradiation‑induced cell death. Therefore, the current study revealed that miR‑148b inhibited NSCLC cell proliferation and the EMT, and increased the radiosensitivity of NSCLC cells by inhibiting ROCK1 expression. Therefore, miR‑148b/ROCK1 signaling may be a novel therapeutic target to inhibit the growth of NSCLC cells and enhance the effects of radiotherapy to treat patients with NSCLC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Murray N: Reality check for pemetrexed and maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 32:482–483. 2014. View Article : Google Scholar : PubMed/NCBI
3	Herbst RS, Heymach JV and Lippma SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
4	Claassens L, van Meerbeeck J, Coens C, Quinten C, Ghislain I, Sloan EK, Wang XS, Velikova G and Bottomley A: Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol. 29:2104–2120. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C and Shen H: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
6	Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R and Salgia R: Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 5:1392–1433. 2014. View Article : Google Scholar : PubMed/NCBI
7	Scagliotti GV and Novello S: Adjuvant therapy in completely resected non-small-cell lung cancer. Curr Oncol Rep. 5:318–325. 2003. View Article : Google Scholar : PubMed/NCBI
8	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
9	Li L, Chen YY, Li SQ, Huang C and Qin YZ: Expression of miR-148/152 family as potential biomarkers in non-small-cell lung cancer. Med Sci Monit. 21:1155–1161. 2015. View Article : Google Scholar : PubMed/NCBI
10	Socinski MA: Seeking new options for the treatment of small-cell lung cancer. Lung cance. 50 Suppl 1:S25–S26. 2005. View Article : Google Scholar
11	Ranganathan K and Sivasankar V: MicroRNAs-Biology and clinical applications. J Oral Maxillofac Pathol. 18:229–234. 2014. View Article : Google Scholar : PubMed/NCBI
12	Li MH, Fu SB and Xiao HS: Genome-wide analysis of microRNA and mRNA expression signatures in cancer. Acta Pharmacol Sin. 36:1200–1211. 2015. View Article : Google Scholar : PubMed/NCBI
13	Rutnam ZJ and Yang BB: The involvement of microRNAs in malignant transformation. Histol Histopathol. 27:1263–1270. 2012.PubMed/NCBI
14	Winter J, Jung S, Keller S, Gregory RI and Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
15	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
16	Zimmerman AL and Wu S: MicroRNAs, cancer and cancer stem cells. Cancer Lett. 300:10–19. 2011. View Article : Google Scholar : PubMed/NCBI
17	Kishikawa T, Otsuka M, Ohno M, Yoshikawa T, Takata A and Koike K: Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol. 21:8527–8540. 2015. View Article : Google Scholar : PubMed/NCBI
18	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
19	Skrzypski M, Dziadziuszko R and Jassem J: MicroRNA in lung cancer diagnostics and treatment. Mutat Res. 717:25–31. 2011. View Article : Google Scholar : PubMed/NCBI
20	Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z and Meng Z: The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol. 7:334–345. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wang X and Chen Z: MicroRNA-19a functions as an oncogenic microRNA in non-small cell lung cancer by targeting the suppressor of cytokine signaling 1 and mediating STAT3 activation. Int J Mol Med. 35:839–846. 2015. View Article : Google Scholar : PubMed/NCBI
22	Sun W, Ma Y, Chen P and Wang D: MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-beta/Smad2/STAT3/STAT5 pathway. Mol Med Rep. 11:3854–3859. 2015. View Article : Google Scholar : PubMed/NCBI
23	Huang MX: Down-expression of circulating micro ribonucleic acid (miRNA)-148/152 family in plasma samples of non-small cell lung cancer patients. J Cancer Res Ther. 12:671–675. 2016. View Article : Google Scholar : PubMed/NCBI
24	Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, Liu SH, Yi QT, Li J and Song CH: Serum miR-152, miR-148a, miR-148b and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 36:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Xie WY, Zhou XD, Yang J, Chen LX and Ran DH: Inhibition of autophagy enhances heat-induced apoptosis in human non-small cell lung cancer cells through ER stress pathways. Arch Biochem Biophys. 607:55–66. 2016. View Article : Google Scholar : PubMed/NCBI
27	Orso F, Quirico L, Virga F, Penna E, Dettori D, Cimino D, Coppo R, Grassi E, Elia AR, Brusa D, et al: miR-214 and miR-148b Targeting Inhibits dissemination of melanoma and breast cancer. Cancer Res. 76:5151–5162. 2016. View Article : Google Scholar : PubMed/NCBI
28	Song Y, Sun J, Xu Y, Liu J, Gao P, Chen X, Zhao J and Wang Z: Microarray analysis of long non-coding RNAs related to microRNA-148b in gastric cancer. Neoplasma. 64:199–208. 2017. View Article : Google Scholar : PubMed/NCBI
29	Wang R, Ye F, Zhen Q, Song T, Tan G, Chu W, Zhang Y, Lv B, Zhao X and Liu J: MicroRNA-148b is a potential prognostic biomarker and predictor of response to radiotherapy in non-small-cell lung cancer. J Physiol Biochem. 72:337–343. 2016. View Article : Google Scholar : PubMed/NCBI
30	Kharbanda A, Rajabi H, Jin C, Alam M, Wong KK and Kufe D: MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget. 5:8893–8905. 2014. View Article : Google Scholar : PubMed/NCBI
31	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
32	Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ and Yang J: Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 71:245–254. 2011. View Article : Google Scholar : PubMed/NCBI
33	Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris ES, Peros G, Rallis G, Lapas C, Karakitsos P, Terracciano LM and Lugli A: Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Human Pathol. 42:1888–1896. 2011. View Article : Google Scholar
34	Schmalhofer O, Brabletz S and Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
35	You S, Li R, Park D, Xie M, Sica GL, Cao Y, Xiao ZQ and Deng X: Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol Cancer Ther. 13:606–616. 2014. View Article : Google Scholar : PubMed/NCBI
36	Kumper S, Mardakheh FK, McCarthy A, Yeo M, Stamp GW, Paul A, Worboys J, Sadok A, Jørgensen C, Guichard S and Marshall CJ: Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. ELife. 5:e129942016. View Article : Google Scholar : PubMed/NCBI
37	Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL and Der CJ: ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 72:5338–5347. 2012. View Article : Google Scholar : PubMed/NCBI
38	Li J, Song Y, Wang Y, Luo J and Yu W: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem. 380:277–282. 2013. View Article : Google Scholar : PubMed/NCBI
39	Cimino D, De Pittà C, Orso F, Zampini M, Casara S, Penna E, Quaglino E, Forni M, Damasco C, Pinatel E, et al: miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS and CSF1. FASEB J. 27:1223–1235. 2013. View Article : Google Scholar : PubMed/NCBI